Organic Process Research & Development 2004, 8, 754−768
Development of an Efficient Process for the Preparation of Sch 39166:
Aziridinium Chemistry on Scale
Dinesh Gala,* Vilas H. Dahanukar,* Jeffery M. Eckert, Brian S. Lucas, Doris P. Schumacher, and Ilia A. Zavialov
Schering-Plough Research Institute, Department of Synthetic Chemistry, 1011 Morris AVenue,
Union, New Jersey 07083, U.S.A.
Patrik Buholzer, Peter Kubisch, Ingrid Mergelsberg, and Dominik Scherer
Chemical DeVelopment Department, Werthenstein Chemie AG, 6105 Schachen, Switzerland
Abstract:
hundred kilograms of Sch 39166. The aziridinium route was
demonstrated in the laboratory to provide a quick access to
1. However, the following challenges were identified with
this approach which required additional work to make it a
robust, plant-suitable process capable of making large
quantities of Sch 39166 needed to support clinical trials: (1)
An efficient and cheap synthesis of key starting material 2
was necessary. (2) N-Alkylation of 2 to 3 was slow and
required very long reaction times. (3) The yields obtained
in the aziridinium formation and opening step were highly
variable (45-60%), and an excess (2.1 equiv) of the
expensive Grignard reagent 4 was required to obtain these
moderate yields. The purity of isolated product varied from
85 to 95%, requiring a chromatographic purification of 5.17
Overall, the mechanistic aspects of the chemistry involved
in this transformation were poorly understood. (4) The
cyclization/reduction protocol for the conversion of 5 to 6
A large-scale synthesis of a tricyclic D1/D5 dopamine antagonist
based on regio- and stereoselective ring opening of an aziri-
dinium ion with a Grignard reagent was optimized and scaled
up.
Introduction
Sch 39166 (1) is a potent dopamine D-1 antagonist that
was initially developed to treat schizophrenia.1 Subsequent
in vivo animal autoradiography studies2 demonstrated that
1 was a highly selective D1/D5 antagonist. Since the
neurotransmitter dopamine is involved in the reward mech-
anism that induces craving, 1 was shown in animal models
to reduce cravings for addictive substances (cocaine, nicotine,
alcohol, etc.) and food.3 New phase II trials showed that 1
reduced the euphoric effects of cocaine,4 but was not effective
in completely treating the addiction.5 Additional clinical
studies were planned to evaluate 1 in reducing cravings for
food (to treat obesity) and nicotine. With renewed interest
in conducting phase II and phase III clinical trials of 1, a
commercial synthesis was urgently required to support these
activities and future marketing needs.
(8) Kalkote, U. R.; Choudhary, A. R.; Natu, A. A.; Ayyangar, N. R. Synth.
Commun. 1991, 21, 1129-1135.
(9) Purchase, C. F.; Goel, O. P. J. Org. Chem. 1991, 56, 457-459.
(10) (a) Leonard, N. J.; Paukstelis, J. V. J. Org. Chem. 1965, 30, 821. (b) Olah,
G. A.; Szilagyi, P. J. J. Am. Chem. Soc. 1969, 91, 2949-2955. (c) Golding,
B. T.; Kebbell, M. J.; Lockhart, I. M. J. Chem. Soc., Perkin Trans. 2 1987,
705-713.
(11) (a) Andrews, D. R.; Dahanukar, V. H.; Eckert, J. M.; Gala, D.; Lucas, B.
S.; Schumacher, D. P.; Zavialov I. A. Tetrahedron Lett. 2002, 43, 6121-
6125. (b) Dahanukar, V. H.; Zavialov, I. A. Curr. Opin. Drug DiscoVery
DeV. 2002, 5, 918-927.
Several different syntheses of 1 were explored,6,7 and the
approach based on aziridinium chemistry7 proved to be the
most attractive. This report deals with the chemistry aspects
of process development and optimization of the aziridinium
route (Scheme 1) that enabled us to manufacture several
(12) Other sulfonyl choride reagents investigated as activating reagents (ben-
zenesulfonyl chloride, 4-chlorobenzenesulfonyl chloride, 4-nitrobenzene-
sulfonyl chloride, and MsCl) showed no advantage over p-TsCl. Other
reagents (methanesulfonic anhydride, p-toluenesulfonyl imidazole, carbon-
yldimidazole, thionyl chloride, trifluoroacetic anhydride, and oxalyl chloride)
also proved to be inferior to p-TsCl.
(1) Karlsson, P.; Smith, L.; Farde, L.; Haernryd, C.; Sedvall, G.; Wiesel, F.-A.
Psychopharmacology 1995, 121, 309-316.
(2) Duffy, R. A.; Hunt, M. A.; Wamsley, J. K.; McQuade, R. D. J. Chem.
Neuroanat. 2000, 19, 41-46.
(3) Coffin, V.; Glue, P. W. Methods for reducing craving in mammals. WO
9921540-A2, 1999.
(4) Romach, M. K.; Glue, P.; Kampman, K.; Kaplan, H. L.; Somer, G. R.;
Poole, S.; Clarke, L.; Coffin, V.; Cornish, J. O’Brien, C. P.; Sellers, E. M.
Arch. Gen. Psychiatry 1999, 56, 1101-1106.
(13) 31P NMR (THF-d8, 161.98 MHz) spectra were recorded using H3PO4 as an
external reference standard.
(14) Erdik, E. Tetrahedron 1984, 40, 641-657.
(15) Several copper salts other than CuCl and CuCN were screened in catalytic
amounts (10 mol %): CuBr, CuI, CuSCN, CuSPh, Cu(OtBu), CuCl2,
Cu(OAc)2, Cu(BF4)2, Cu(OTf)2, copper (II) naphthenate, copper (II)
acetylacetonate, copper (II) tifluoroacetylacetonate, copper (II) benzoyl-
acetonate, lithium 2-thienylcyanocuprate, and Cu(I) phenylacetylide. Other
metal salts (Cr, Fe, Mn, and Ni) failed to show any improvement in the
reaction of 16 with 4.
(16) In the laboratory, after forming 15b at -20 °C, it was mixed with 4 at
various temperatures and held for several hours. Aliquots were taken and
analyzed periodically by HPLC to quantitate the amount of product 5. This
work showed that the reaction of 4 with 16 was sluggish below 0 °C and
proceeded faster at 25-35 °C.
(5) Nann-Vernotica, E.; Donny, E. C.; Bigelow, G. E.; Walsh, S. L. Psycho-
pharmacology 2001, 155, 338-347.
(6) (a) Wu, G.; Wong, Y.; Steinman, M.; Tormos, W.; Schumacher, D. P.;
Love, G. M.; Shutts, B. P.; Org. Process Res. DeV. 1997, 1, 359-364. (b)
Draper, R. W.; Hou, D.; Iyer, R.; Lee, G. M.; Liang, J. T.; Mas, J. L.;
Vater, E. J. V. Org. Process Res. DeV. 1998, 2, 186-193. (c) Hou, D.;
Schumacher, D. Curr. Opin. Drug DiscoVery DeV. 2001, 4, 792-799.
(7) Draper, R. W.; Hou, D.; Iyer, R.; Lee, G. M.; Liang, J. T.; Mas, J. L.;
Tormos, W.; Vater, E. J.; Gunter, F.; Mergelsberg, I.; Scherer, D. Org.
Process Res. DeV. 1998, 2, 175-185.
(17) This would be a large waste burden for a commercial process; hence, it
was to be avoided at any cost.
754
•
Vol. 8, No. 5, 2004 / Organic Process Research & Development
10.1021/op0402026 CCC: $27.50 © 2004 American Chemical Society
Published on Web 08/03/2004